secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-07-06T13:13:16+00:00
Accession:  0001104659-26-080613
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma closes merger with InnocsAI; issues 11.2M common shares and 158.9K Series A preferred
--------------------------------------------------------------------------------

- Merger closed July 2, 2026; Liminatus acquired InnocsAI, a CAR-T therapy company.
- Issued 11,188,729 common shares and 158,881.1271 Series A Preferred shares (each convertible into 10,000 common shares).
- Total consideration 1.6B shares at $0.20/share, but capped at 19.99% of pre-closing outstanding common stock.
- Series A Preferred non-voting, convertible only after stockholder approval; meeting to be held.
- Registration rights and non-compete agreements executed with InnocsAI members and key employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926080613/0001104659-26-080613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926080613/tm2619730d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer